Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Amgen

Growth was offset by declines for flagship products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen
3Q Revenues: $5.7 billion (-3%)
3Q Earnings: $2.0 billion (+6%)
YTD Revenues: $17.2 billion (-2%)
YTD Earnings: $6.1 billion (-5%)  
Comments: Enbrel sales were $1.4 billion in the quarter, up 6%. Prolia sales were up 18% to $630 million. Repatha sales were up 40% to $168 million. Aimovig sales totaled $66 million in the quarter. Parsabiv sales were up 54% to $157 million. KYPROLIS sales were $266 million, up 15%. BLINCYTO sales were up 47% to $85 million. Growth was offset by declines for flagship products. Neulasta, sales were down 32% to $711 million. Neupogen sales were down 36% to $54 million. Epogen sales were down 15% to $215 million. Aranesp sales were down 5% to $452 million. Sensipar/Mimpara sales were down 73% to $109 million

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters